US-based Halozyme Therapeutics has signed a worldwide collaboration and licence agreement with Janssen Biotech to develop and commercialise subcutaneous products by using Enhanze technology.

Halozyme’s Enhanze technology was based on a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, an extracellular matrix component, to aid in the dispersion and absorption of other injected therapeutic drugs.

Halozyme Therapeutics president and CEO Dr Helen Torley said: “This new global licensing agreement further validates our Enhanze platform technology, which we believe may benefit a growing number of patients worldwide by making therapies more convenient.”

“This new global licensing agreement further validates our Enhanze platform technology.”

As part of the agreement, Halozyme has granted a worldwide licence to Janssen to develop and commercialise products for up to five targets combining rHuPH20 with Janssen’s proprietary compounds.

The deal will allow Halozyme to receive an initial payment of $15m, and is also eligible to receive additional payments upon Janssen’s achievement of specified development, regulatory and sales-based milestones, totalling up to $566m.

Based on net sales of products using the Enhanze technology, Halozyme is also entitled to royalty payments.

Janssen will also be provided with an access to Halozyme’s expertise in developing and applying rHuPH20 to its targets, under the collaboration.

The company will secure a worldwide and exclusive license to develop and commercialise product combinations of rHuPH20 and target compounds resulting from the collaboration.

Halozym noted that rHuPH20 has been demonstrated to remove traditional limitations on the volume of biologics that can be delivered subcutaneously.